Q1 2018 EPS Estimates for Kadmon Co. Boosted by Analyst (KDMN)

Kadmon Co. (NYSE:KDMN) – Equities research analysts at Jefferies Group raised their Q1 2018 earnings per share (EPS) estimates for shares of Kadmon in a research note issued on Wednesday, according to Zacks Investment Research. Jefferies Group analyst B. Amin now expects that the company will post earnings of ($0.23) per share for the quarter, up from their prior estimate of ($0.50). Jefferies Group currently has a “Buy” rating and a $16.00 price target on the stock. Jefferies Group also issued estimates for Kadmon’s Q2 2018 earnings at ($0.24) EPS, Q3 2018 earnings at ($0.23) EPS, Q4 2018 earnings at ($0.24) EPS, FY2018 earnings at ($0.96) EPS, FY2019 earnings at ($1.06) EPS, FY2020 earnings at ($1.12) EPS, FY2021 earnings at ($1.20) EPS and FY2022 earnings at ($0.33) EPS.

How to Become a New Pot Stock Millionaire

Kadmon (NYSE:KDMN) last announced its quarterly earnings results on Tuesday, March 6th. The company reported ($0.24) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.36) by $0.12. The firm had revenue of $1.50 million for the quarter, compared to analyst estimates of $3.07 million. During the same period in the previous year, the business posted ($0.50) earnings per share. The business’s revenue for the quarter was down 65.1% compared to the same quarter last year.

A number of other analysts have also commented on the company. Zacks Investment Research raised Kadmon from a “strong sell” rating to a “hold” rating in a research note on Saturday, March 10th. HC Wainwright reissued a “buy” rating and set a $25.00 price target on shares of Kadmon in a research note on Friday, March 9th. Finally, Piper Jaffray reissued a “positive” rating and set a $9.00 price target (up from $7.00) on shares of Kadmon in a research note on Tuesday, February 13th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $11.45.

Shares of KDMN stock traded down $0.12 during mid-day trading on Friday, reaching $4.13. 318,412 shares of the stock traded hands, compared to its average volume of 997,782. Kadmon has a 1-year low of $2.05 and a 1-year high of $5.86. The firm has a market capitalization of $334.23, a price-to-earnings ratio of -2.91 and a beta of 3.90.

Several institutional investors and hedge funds have recently modified their holdings of KDMN. Wells Fargo & Company MN boosted its holdings in Kadmon by 17.0% during the second quarter. Wells Fargo & Company MN now owns 60,033 shares of the company’s stock worth $234,000 after buying an additional 8,742 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Kadmon by 166.0% in the second quarter. Vanguard Group Inc. now owns 1,508,869 shares of the company’s stock valued at $5,870,000 after buying an additional 941,549 shares during the last quarter. Goldman Sachs Group Inc. acquired a new position in shares of Kadmon in the second quarter valued at approximately $114,000. Bank of New York Mellon Corp acquired a new position in shares of Kadmon in the third quarter valued at approximately $119,000. Finally, AE Wealth Management LLC raised its position in shares of Kadmon by 33.6% in the third quarter. AE Wealth Management LLC now owns 323,161 shares of the company’s stock valued at $1,083,000 after buying an additional 81,226 shares during the last quarter. Institutional investors own 61.71% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Q1 2018 EPS Estimates for Kadmon Co. Boosted by Analyst (KDMN)” was originally posted by Enterprise Leader and is owned by of Enterprise Leader. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark law. The legal version of this piece of content can be accessed at https://theenterpriseleader.com/2018/04/02/q1-2018-eps-estimates-for-kadmon-holdings-inc-kdmn-lifted-by-jefferies-group.html.

About Kadmon

Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics within autoimmune and fibrotic, oncology, and genetic diseases. The company markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including those indicated for the management of rare diseases.

Get a free copy of the Zacks research report on Kadmon (KDMN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply